{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:14:05Z","timestamp":1783620845684,"version":"3.55.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>National clinical guidelines recommend biomarker testing to identify actionable alterations across cancers, supporting personalized treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective database study characterized biomarker testing patterns among adult patients newly diagnosed with metastatic non-small cell lung cancer (NSCLC), prostate cancer, or bladder cancer (January 2018\u2013December 2022), receiving care within a large regional community oncology network in the West South-Central United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 18 491 patients with NSCLC, 20 810 with prostate cancer, and 4120 with bladder cancer, 7383 (40%), 4985 (24%), and 888 (22%), respectively, had metastatic disease. For these metastatic subgroups, biomarker testing rates were 80% (NSCLC), 34% (prostate), and 42% (bladder). Median time from disease diagnosis to first test order was 10\u2009days (NSCLC), 98\u2009days (prostate), and 23\u2009days (bladder), with differences observed across racial and ethnic groups. Among tested patients, actionable mutations were identified in 29% (NSCLC), 25% (prostate), and 14% (bladder) of patients, and targeted therapy was received by 54%, 15%, and 38% of these patients, respectively. Among patients who initiated treatment prior to receipt of test results, 72% (NSCLC), 12% (prostate), and 30% (bladder) subsequently switched to targeted therapy following a positive result. Testing rates increased between 2018 and 2022 for all cohorts; result turnaround times improved in prostate and bladder cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biomarker testing was highest in metastatic NSCLC and lower in prostate and bladder cancer in this community oncology setting. Despite improvements over time, gaps remain in timely testing and use of targeted therapies, highlighting opportunities to optimize precision oncology implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag243","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:06:47Z","timestamp":1782713207000},"source":"Crossref","is-referenced-by-count":0,"title":["Biomarker testing patterns among patients newly diagnosed with metastatic non-small cell lung cancer, prostate cancer, and bladder cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6239-1017","authenticated-orcid":false,"given":"Siraje","family":"Mahmud","sequence":"first","affiliation":[{"name":"Precision Health Informatics, LLC , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4113-713X","authenticated-orcid":false,"given":"Lisa","family":"Dwyer Orr","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Titusville, NJ 08560,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5362-0619","authenticated-orcid":false,"given":"Mika","family":"Cline","sequence":"additional","affiliation":[{"name":"Texas Oncology , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-9928","authenticated-orcid":false,"given":"Ayda","family":"Mirsalehi","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7664-244X","authenticated-orcid":false,"given":"Monica","family":"Lisi","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1668-8797","authenticated-orcid":false,"given":"Laura","family":"Ensley","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6474-2045","authenticated-orcid":false,"given":"Lorraine","family":"Brisbin","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3570-1471","authenticated-orcid":false,"given":"R Steven","family":"Paulson","sequence":"additional","affiliation":[{"name":"Texas Oncology , Dallas, TX 75251,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2026070913270295700_oyag243-B1","doi-asserted-by":"publisher","first-page":"e1743","DOI":"10.1634\/theoncologist.2019-0864","article-title":"Value of precision medicine in advanced non-small cell lung cancer: real-world outcomes associated with the use of companion diagnostics","volume":"25","author":"John","year":"2020","journal-title":"Oncologist"},{"key":"2026070913270295700_oyag243-B2","year":"2025"},{"key":"2026070913270295700_oyag243-B3","year":"2025"},{"key":"2026070913270295700_oyag243-B4","year":"2025"},{"key":"2026070913270295700_oyag243-B5","doi-asserted-by":"publisher","first-page":"e2400039","DOI":"10.1200\/PO.24.00039","article-title":"Real-world biomarker test ordering practices in non-small cell lung cancer: interphysician variation and association with clinical outcomes","volume":"8","author":"Baron","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026070913270295700_oyag243-B6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/jnci\/djae225","article-title":"Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake","volume":"117","author":"Tuminello","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026070913270295700_oyag243-B7","doi-asserted-by":"publisher","first-page":"100522","DOI":"10.1016\/j.ctarc.2022.100522","article-title":"Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the us oncology network","volume":"31","author":"Nadler","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"2026070913270295700_oyag243-B8","year":"2017"},{"key":"2026070913270295700_oyag243-B9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","article-title":"Genetic testing in men with metastatic castration-resistant prostate cancer","volume":"10","author":"Barata","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026070913270295700_oyag243-B10","doi-asserted-by":"publisher","first-page":"e2423186","DOI":"10.1001\/jamanetworkopen.2024.23186","article-title":"Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers","volume":"7","author":"Hage Chehade","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026070913270295700_oyag243-B11","doi-asserted-by":"publisher","first-page":"e901","DOI":"10.1016\/j.cllc.2021.05.006","article-title":"Understanding contemporary molecular biomarker testing rates and trends for metastatic nsclc among community oncologists","volume":"22","author":"Waterhouse","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026070913270295700_oyag243-B12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2024.42.4_suppl.97","article-title":"N. Real-world genomic testing patterns in patients with prostate cancer","volume":"41","author":"Kaakour","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070913270295700_oyag243-B13","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","article-title":"Real-world genetic testing patterns in metastatic castration-resistant prostate cancer","volume":"17","author":"Shore","year":"2021","journal-title":"Future Oncol"},{"key":"2026070913270295700_oyag243-B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2022.03.004","article-title":"Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the us oncology network","volume":"166","author":"Robert","year":"2022","journal-title":"Lung Cancer"},{"key":"2026070913270295700_oyag243-B15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2021.7083","article-title":"Associations between medicaid insurance, biomarker testing, and outcomes in patients with advanced nsclc","volume":"20","author":"Gross","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070913270295700_oyag243-B16","author":"American Cancer Society I","year":"2024"},{"key":"2026070913270295700_oyag243-B17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070913270295700_oyag243-B18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40487-024-00271-w","article-title":"The importance of biomarker testing in the treatment of advanced non-small cell lung cancer: a podcast","volume":"12","author":"Hirsch","year":"2024","journal-title":"Oncol Ther"},{"key":"2026070913270295700_oyag243-B19","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"2026070913270295700_oyag243-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026070913270295700_oyag243-B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: Biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"2026070913270295700_oyag243-B22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","article-title":"The roles of fgfr3 and c-myc in urothelial bladder cancer","volume":"15","author":"Bogale","year":"2024","journal-title":"Discov Oncol"},{"key":"2026070913270295700_oyag243-B23","doi-asserted-by":"publisher","first-page":"e433138","DOI":"10.1200\/EDBK_433138","article-title":"Advancing prostate cancer care: Treatment approaches to precision medicine, biomarker innovations, and equitable access","volume":"44","author":"Fenton","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026070913270295700_oyag243-B24","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1002\/mco2.455","article-title":"Targeted therapies in bladder cancer: signaling pathways, applications, and challenges","volume":"4","author":"Peng","year":"2023","journal-title":"MedComm (2020)"},{"key":"2026070913270295700_oyag243-B25","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.3390\/cells11203200","article-title":"Biomarker-targeted therapies in non-small cell lung cancer: Current status and perspectives","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"2026070913270295700_oyag243-B26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"2026070913270295700_oyag243-B27","doi-asserted-by":"publisher","first-page":"e2400449","DOI":"10.1200\/PO-24-00449","article-title":"Real-world analysis of disparities in biomarker testing and use of recommended targeted therapies in metastatic non-small cell lung cancer in the United States","volume":"9","author":"Dennis","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"2026070913270295700_oyag243-B28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.cllc.2025.11.017","article-title":"A United States-based real-world study on biomarker testing and rebiopsy rates among patients with non-small cell lung cancer across lines of therapy","volume":"27","author":"Aggarwal","year":"2026","journal-title":"Clin Lung Cancer"},{"key":"2026070913270295700_oyag243-B29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cllc.2023.03.002","article-title":"Real-world biomarker testing patterns in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) in a us community-based oncology practice setting","volume":"24","author":"Sireci","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026070913270295700_oyag243-B30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2022.1167","article-title":"Biomarker testing, treatment uptake, and survival among patients with urothelial cancer receiving gene-targeted therapy","volume":"8","author":"Nimgaonkar","year":"2022","journal-title":"JAMA Oncol."},{"key":"2026070913270295700_oyag243-B31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.2024.42.4_suppl.210","article-title":"Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070913270295700_oyag243-B32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","volume":"28","author":"Armstrong","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070913270295700_oyag243-B33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41391-024-00887-z","article-title":"Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (part 2 of 2)","volume":"28","author":"Serritella","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070913270295700_oyag243-B34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","article-title":"Next-generation sequencing of prostate cancer: Genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","volume":"20","author":"Ikeda","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"2026070913270295700_oyag243-B35","doi-asserted-by":"publisher","first-page":"e2334208","DOI":"10.1001\/jamanetworkopen.2023.34208","article-title":"Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer","volume":"6","author":"Hwang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026070913270295700_oyag243-B36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett"},{"key":"2026070913270295700_oyag243-B37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cam4.4917","article-title":"Racial inequity and other social disparities in the diagnosis and management of bladder cancer","volume":"12","author":"Hasan","year":"2023","journal-title":"Cancer Med"},{"key":"2026070913270295700_oyag243-B38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.euros.2024.07.113","article-title":"A cross-sectional survey of physicians to understand biomarker testing and treatment patterns in patients with prostate cancer in the USA, eu5, Japan, and China","volume":"71","author":"Gratzke","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"2026070913270295700_oyag243-B39","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.amepre.2018.05.028","article-title":"Attitudes toward genomic testing and prostate cancer research among black men","volume":"55","author":"Rogers","year":"2018","journal-title":"Am J Prev Med"},{"key":"2026070913270295700_oyag243-B40","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1002\/cncr.34926","article-title":"The american cancer society national lung cancer roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer","volume":"130","author":"Roy-Chowdhuri","year":"2024","journal-title":"Cancer"},{"key":"2026070913270295700_oyag243-B41","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1002\/cncr.34628","article-title":"The american cancer society national lung cancer roundtable strategic plan: Advancing comprehensive biomarker testing in non-small cell lung cancer","volume":"130","author":"Fox","year":"2024","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag243\/68641277\/oyag243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag243\/68641277\/oyag243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag243\/68641277\/oyag243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:27:08Z","timestamp":1783618028000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag243\/8721312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag243","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,27]]},"article-number":"oyag243"}}